<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586063</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-52014-191</org_study_id>
    <nct_id>NCT03586063</nct_id>
  </id_info>
  <brief_title>Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis</brief_title>
  <official_title>A Multicenter Observational Study of Diphereline 3.75 mg Treatment Effectiveness in Russian Women Suffering From Internal Genital Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe Gonadotropin-Releasing Hormone agonists (GnRH-a) treatment effectiveness on
      reduction of internal genital endometriosis symptom - menorrhagia - in different disease
      stages I, II, III in the Russian patient population scheduled for treatment with Diphereline
      3,75 mg - assessment performed six months after the last injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2011</start_date>
  <completion_date type="Actual">December 24, 2014</completion_date>
  <primary_completion_date type="Actual">December 24, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of disease symptom menorrhagia (none-mild-moderate-severe) in different disease stages I, II, III in the Russian subject population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>Change from baseline to up to 6 months after the last injection (up to month 11)</time_frame>
    <description>A responder is defined as a subject with menorrhagia reduction at least by one level (i.e. from severe to moderate, from moderate to mild, from mild to none).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' age at study entry</measure>
    <time_frame>Baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at the time of internal genital endometriosis diagnosis</measure>
    <time_frame>Baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gynaecological history</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>Age of menarche, hereditary load in onco-gynaecology, sexually transmitted infections, gynaecological surgical procedures, number of pregnancies, medical abortions, miscarriages, normal deliveries, coexisting gynaecological diseases, somatic diseases, if any.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data on fertility: primary and secondary sterility</measure>
    <time_frame>Baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical history</measure>
    <time_frame>Baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medications and non drug therapy for internal endometriosis treatment</measure>
    <time_frame>Baseline (Day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of disease symptom dysmenorrhea (none-mild-moderate-severe) in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>On the day of the last injection (up to Month 5)</time_frame>
    <description>A full responder is defined as the person with a reduction of intensity of at least one level for all symptoms of at least mild intensity at baseline (i.e. from severe to moderate, from moderate to mild, from mild to none).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of disease symptom menorrhagia (none-mild-moderate-severe) in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>On the day of the last injection (up to Month 5)</time_frame>
    <description>A full responder is defined as the person with a reduction of intensity of at least one level for all symptoms of at least mild intensity at baseline (i.e. from severe to moderate, from moderate to mild, from mild to none).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of disease symptom metrorrhagia (none-mild-moderate-severe)</measure>
    <time_frame>On the day of the last injection (up to Month 5)</time_frame>
    <description>A full responder is defined as the person with a reduction of intensity of at least one level for all symptoms of at least mild intensity at baseline (i.e. from severe to moderate, from moderate to mild, from mild to none).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of disease symptom pelvic pain (none-mild-moderate-severe) in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>On the day of the last injection (up to Month 5)</time_frame>
    <description>A full responder is defined as the person with a reduction of intensity of at least one level for all symptoms of at least mild intensity at baseline (i.e. from severe to moderate, from moderate to mild, from mild to none).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine volume in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>Baseline (Day 1) and on the day of the last injection (up to Month 5)</time_frame>
    <description>Measured by ultrasound and calculated by the equation 0,523 x a x b x c, where a, b and c stand for uterine length, width and thickness, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine shape (bimanual pelvic examination) in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>Baseline (Day 1) and on the day of the last injection (up to Month 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internal genital endometriosis symptom metrorrhagia in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>Change from baseline (Day 1) to 6 months after the last injection (up to Month 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internal genital endometriosis symptom dysmenorrhea in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>Change from baseline (Day 1) to 6 months after the last injection (up to Month 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internal genital endometriosis symptom pelvic pain in different disease stages I, II, III in the Russian patient population scheduled for treatment with Diphereline 3.75 mg</measure>
    <time_frame>Change from baseline (Day 1) to 6 months after the last injection (up to Month 11)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproduction function will be assessed by the number of patients got pregnant 6 and 9 months after the end of treatment with Diphereline 3.75mg</measure>
    <time_frame>6 and 9 months after the end of treatment with Diphereline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproduction function will be assessed by the number of patients who avoided hysterectomy/ did not receive a surgical treatment 6 and 9 months after the end of treatment with Diphereline 3.75mg</measure>
    <time_frame>6 and 9 months after the end of treatment with Diphereline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diphereline 3.75 mg treatment practice will be assessed by the number of scheduled/ performed injections with treatment schedule (each 28 days) in line with treatment administration approved in Russian Federation</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diphereline 3.75 mg treatment practice will be assessed by patient compliance with treatment schedule (each 28 days) in line with treatment administration approved in Russian Federation</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">465</enrollment>
  <condition>Internal Endometriosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>This is a non-interventional (observational) national multicentre prospective study.
Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.
The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Antenatal clinics and Medical centres
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women aged 25-40 years old

          -  With symptomatic internal genital endometriosis - at least mild menorrhagia present or
             worse

          -  Internal genital endometriosis diagnosis is based on enlarged uterus detected by
             pelvic bimanual examination and ultrasound examination (stages I-II-III by Demidov in
             accordance with ultrasound results not earlier than 2 months before first injection

          -  Naive patients who have never been prescribed a GnRH agonist

        Exclusion Criteria:

          -  Pregnant subjects

          -  Subjects with hypersensitivity to GnRH analogue or to one of its excipients

          -  Subjects treated with any other investigational drug within the last 30 days before
             study entry

          -  Subjects' refusal to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moscow regional perinatal center</name>
      <address>
        <city>Balashikha</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific center of Family Health Problems and Human reproduction of Siberian branch of RAMS</name>
      <address>
        <city>Irkutsk</city>
        <zip>664003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEI Irkutsk State medical refresher institute</name>
      <address>
        <city>Irkutsk</city>
        <zip>664011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal healthcare institution &quot;City hospital #11&quot;</name>
      <address>
        <city>Kazan</city>
        <zip>420127</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City hospital #2, Krasnodar multi-field medical diagnostic association, endoscopic gynecology center</name>
      <address>
        <city>Krasnodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI &quot;Regional clinical hospital #1 named after S. Ochapovskiy&quot;</name>
      <address>
        <city>Krasnodar</city>
        <zip>350029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI &quot;City Clinical Hospital #79&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115487</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Research Center of Obstetrics, Gynecology and Perinatology named after V. Kulakov&quot; on the base of City clinical hospital named after S. Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment rehabilitation Center of Roszdrav</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of Civil aviation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CM-Clinic</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI &quot;Endocrinology Research Center&quot; of the Ministry of Health and Social Development of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FBHI &quot;Volga regional medical center&quot; of Federal Medical-Biological agency, gynecological department of clinical hospital #1</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental healthcare institution &quot;Road clinical hospital on Gor'kiy station RZhD NChS</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of new medical technologies in academic town</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Zdravitsa</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Clinic</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical hospital №123 of FMBA of Russia</name>
      <address>
        <city>Odintsovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI &quot;City hospital #8&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical hospital #1 of FSI &quot;Southern federal district medical center&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov state medical university, department of obstetrics and gynaecology #3, based on SHI &quot;Region hospital #2&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI &quot;Regional hospital #2&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSI &quot;Rostov Research institution of obstetrics and pediatry&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>350029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City hospital #3 of the Holy Reverend Martyr Elizabeth</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-West State Medical University named after I. Mechnikov on the base of maternity hospital #17</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific-Research Institute of obstetrics and gynecology named after D.O. Otto of Russian Academy of Medical Science</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical centre IDK</name>
      <address>
        <city>Samara</city>
        <zip>443067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental healthcare institution &quot; Railway Clinical Hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410004</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI Saratov Regional Centre of Family Planning and Reproduction</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental healthcare institution &quot;Departmental clinical hospital on station Ufa RZHD&quot;</name>
      <address>
        <city>Ufa</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State-Funded Educational Institution of Higher Vocational Education &quot;Volgogradskii State Medical University of Roszdrav on the base of Hospital #1</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center &quot;Yunona&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal clinical healthcare Institution of Yaroslavl region &quot;Primary healthcare unit NYa ORP&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 12, 2018</last_update_submitted>
  <last_update_submitted_qc>July 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

